W

Notice of Allowability	Application No.	Applicant(s)
	10/673,313	DUFFY ET AL.
	Examiner	Art Unit
	Robert Sellers	1712
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. X This communication is responsive to 16 February 2006.		
2. X The allowed claim(s) is/are <u>1-8,13,14,19,23-25,27 and 28</u> .		
<ul> <li>3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some* c) None of the:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).</li> </ul>		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1)  hereto or 2)  to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
		,
Attachment(s)	5. D Nation of left word D	Andread Appellantia a (DTO 450)
<ol> <li>Notice of References Cited (PTO-892)</li> <li>D Notice of Draftperson's Patent Drawing Review (PTO-948)</li> </ol>		Patent Application (PTO-152)
•	Paper No./Mail Da	te <u>206</u> .
<ol> <li>Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 248/2005</li> </ol>	8), 7. 🛛 Examiner's Amendr	ment/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
· ·	9.  Other	

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Donald R. Palladino on February 23, 2006.

The application has been amended as follows:

Reinstate withdrawn claim 19.

Cancel claims 9-12, 15-18, 20-22, 26 and 29-36.

The following is an examiner's statement of reasons for allowance:

The terminal disclaimers filed February 16, 2006 overcomes the obviousness-type double patenting rejections over copending application no. 11/190,666 and U.S. Patent No. 6,737,163 applied in the non-Final rejection mailed November 25, 2005 (pages 7-8).

The claims are patentable over the closest prior art of Donnelly et al. Patent No. 5,569,733 and Makhlouf et al. Patent No. 5,470,886 for the reasons of record set forth on page 9 of the non-Final rejection. The claimed structure of Formula I differs from the formula of Renner Patent No. 4,562,241 in that the terminal tertiary amino groups are separated from the urethane groups by the moiety  $-R_2$ -(O or N( $R_5$ )-.

Art Unit: 1712

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on the Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Sellers whose telephone number is (571) 272-1093. The examiner can normally be reached on Monday to Friday from 9:30 to 6:00. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866) 217-9197 (toll-free).

Robert Sellers Primary Examiner

Art Unit 1712